Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Association between the reduction of face-to-face appointments and the control of patients with type 2 diabetes mellitus during the Covid-19 pandemic in Catalonia

Ermengol Coma a,*, Queralt Miró b, Manuel Medina a, Francesc X. Marin-Gomez b, Manuel Medina a, Francesc X. Marin-Gomez b, Mència Benítez a, Ariadna Mas h, Mireia Fàbregas a, Francesc Fina a, Yolanda Lejardi h, Josep Vidal-Alaball b, Manuel Medina a

a Primary Care Services Information Systems, Institut Català de la Salut, Barcelona, Spain
b Health Promotion in Rural Areas Research Group, Gerència Territorial de la Catalunya Central, Institut Català de la Salut, Spain
c Unitat de Suport a la Recerca de la Catalunya Central, Fundació Institut Universitari per a la recerca a l’Atenció Primària de Salut Jordi Gol i Gurina, Spain
d Faculty of Medicine. University of Vic - Central University of Catalonia, Vic, Spain
e DAP_Cat Research Group, Gerencia Territorial Barcelona Ciutat, Institut Català de la Salut, Spain
f Foundation University Institute for Primary Health Care Research Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain
g Universitat Autonoma de Barcelona, Spain
h Institut Català de la Salut, Spain
i Equip d’Atenció Primària de Gòtic, Institut Català de la Salut, Barcelona, Spain

ARTICLE INFO

Article history:
Received 22 August 2021
Received in revised form
20 October 2021
Accepted 2 November 2021
Available online 6 November 2021

Keywords:
Covid-19
Primary Care-Diabetes Management
Type 2 diabetes
Quality indicators
Office visits

ABSTRACT

Aim: To analyse the relation between face-to-face appointments and management of patients with type 2 diabetes mellitus (T2DM) visited in primary care practices (PCP).

Methods: Retrospective study in 287 primary care practices (PCPs) attending >300,000 patients with T2DM. We analysed the results of 9 diabetes-related indicators of the Healthcare quality standard, comprising foot and retinopathy screening, blood pressure (BP) and glycemic control; and the incidence of T2DM. We calculated each indicator’s percentage of change in 2020 with respect to the results of 2019.

Results: Indicators’ results were reduced in 2020 compared to 2019, highlighting the indicators of foot and retinopathy screening (-51.6% and -25.7%, respectively); the glycemic control indicator (-21.2%); the BP control indicator (-33.7%) and the incidence of T2DM (-25.6%). Conversely, the percentage of type 2 diabetes patients with HbA1c > 10% increased by 34%.

https://doi.org/10.1016/j.diabres.2021.109127

0168-8227/© 2021 The Authors. Published by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
PCPs with <11 weekly face-to-face appointments offered per professional had greater reductions than those PCPs with more than 40. For instance, a reduction of −60.7% vs −38.2% (p-value < 0.001) in the foot screening’s indicator; −27.5% vs −12.5% (p-value < 0.001) in glycemic control and −40.2 vs −24.3% (p-value < 0.001) in BP control.

Conclusions: Reducing face-to-face visits offered may impact T2DM patients’ follow-up and thus worsen their control.

© 2021 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
To calculate T2DM incidences we included all diagnoses registered in the EHR during the study period in the population older than 14 years old (ICD-10 codes provided in Supplementary Table S1). We calculated annual incidence rates of T2DM per 1000 at-risk population, excluding those with a pre-existing T2DM diagnosis.

2.2. Explanatory variables

All explanatory variables included in the study were also aggregated at the PCP level and were obtained from the same EHR used to calculate EQA indicators. They included sociodemographic variables such as the patient’s mean age, gender (percentage of women), the percentage of immigration from a low-income country and the percentage of nursing home residents. We also included the COVID-19 cumulative incidence calculated as the percentage of the PCP population older than 14 years with a COVID-19 confirmed case until December 2020 to adjust by the health resources earmarked to manage the pandemic. COVID-19 data were obtained from the regional central database of reverse transcriptase polymerase chain reaction (RT-PCR) and lateral flow tests for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

We assessed the socioeconomic status using the validated MEDEA deprivation index [21]. We categorised the MEDEA deprivation index into quartiles where 1st and 4th quartiles are least and most deprived areas, respectively. Rural areas were categorised separately and were defined as areas with <10,000 inhabitants and a population density lower than 150 inhabitants/km².

In addition, some organizational variables were included. Continuity of care was measured using the international index UPC (Usual Provider of Care Index) which measures the proportion of visits performed by the general practice or primary care nurse that the patient visits most frequently out of all visits [22]. This index has been used in ICS’ PCPs as an indicator since 2018 [23]. We have also included the VISUBA variable, an organizational variable used to assess the organizations’ orientation towards the immediacy of primary care consultations. The variable measures the percentage of visits made in schedules managed by the patients’ assigned primary care professional out of the total number of the visits in a PCP. VISUBA variable is thus a continuous scale, where the lower the value the higher the degree of immediate consultation and it has been previously used as a variable to measure those PCP organizations favoring immediate consultations [23].

Finally, we included the mean number of weekly face-to-face appointments per primary care professional offered in the schedules of the GPs and primary care nurses (“Face-to-face” variable). This variable was assessed from September to December 2020, to avoid the influence of the first months of the pandemic and the summer. It was calculated as the sum of the number of visits offered in the September-December period by each GP and nurse of the PCP divided by the number of GPs and nurses of the PCP and by the number of weeks. It included all visits offered to any kind of patient to assess the degree of in-person visits. Each GP in Catalonia has an average 1212 patients older than 14 years old assigned. Face-to-face variable was used as a continuous variable and also was categorized in four groups (weekly number of appointments offered per professional of the PCP): a) 0 to 10; b) 11 to 25; c) 26 to 40 and 4) more than 40.

2.3. Statistical analysis

For each PCP, we calculated the percentage of change in 2020 results of EQA indicators compared to the 2019 results. We also calculated the percentage of change between T2DM cumulative incidence in 2020 compared to 2019. For descriptive analysis, we expressed continuous variables as mean (standard deviation) and we summarised categorical variables as absolute frequency (percentage). For bivariate analyses, we used Pearson correlation coefficient for numerical variables; and T-student test or ANOVA analysis for categorical and numerical values. We adjusted a linear regression model using the percentage of change of each EQA indicator or the percentage of change of T2DM incidence as the main dependent variables. We included in the model those explanatory variables that obtained a p-value of lower than 0.05 in the previous bivariate test at least in one indicator. Adjustment variables with a p-value lower than 0.05 in Wald test were considered significant.

All statistical analyses were conducted using R software version 3.5.1 [24].

2.4. Ethics

This study is part of a project that analyses the impact of COVID-19 pandemic, related control measures and organizational changes on primary care. The project was approved by the Clinical Research Ethics Committee of the IDIAP Jordi Gol (project code 20/172-PCV). The study authors did not access identified patient-level data for these analyses that were conducted on aggregated data only (results of quality indicators and other variables at a PCP level).

3. Results

In our study, we included 287 PCPs which have a total assigned population of 4,934,404 people older than 14 years, including 381,917 patients with T2DM. Table 1 summarizes the baseline characteristics of these PCPs: 34.5% of the PCPs were in rural areas and the mean assigned population per PCP was 17,193 patients older than 14 years old. 15.7% of the PCPs offered less than 11 weekly face-to-face appointments per professional from September to December 2020 on average and 12.6% offered more than 40. Continuity of care was reduced by ~10.9% in 2020 compared to 2019 and mean cumulative incidence of COVID-19 per PCP until December 2020 was 15.1%. Rural PCPs had significantly a greater mean age, less size, fewer covid-19 incidence and fewer reduction of continuity of care than urban PCPs (Table 1).

Table 2 shows the percentage of change of T2DM indicators and T2DM incidence in 2020 compared to 2019. The overall T2DM incidence was reduced by ~25.6% (95% CI: –27.9 to –23.3) in 2020. Diabetic foot screening was the indicator with greater reduction with ~51.6% (95% CI: –53.9 to –49.4). HbA1c control and BP control indicators were also reduced by ~21.2%
Table 1 – Baseline characteristics of all the PCP included in the study. Continuous variables are presented with mean (standard deviation) and categorical variables are presented with absolute frequency (percentage).

| Variables                        | Value                                                                 | Total (N = 287) | Rural (N = 99) | Urban (N = 188) | P-value |
|----------------------------------|-----------------------------------------------------------------------|-----------------|----------------|-----------------|---------|
| Socioeconomic status             | Number (%) of Urban - Quartile 1 (Least deprived)                     | 48 (16.7)       |                 |                 |         |
| Socioeconomic status             | Number (%) of Urban - Quartile 2                                     | 36 (12.5)       |                 |                 |         |
| Socioeconomic status             | Number (%) of Urban - Quartile 3                                     | 51 (17.8)       |                 |                 |         |
| Socioeconomic status             | Number (%) of Urban - Quartile 4 (Most deprived)                     | 53 (18.5)       |                 |                 |         |
| Rurality                         | Number (%) of rural PCP                                             | 99 (34.5)       |                 |                 |         |
| Sex                              | % of women                                                            | 50.8 (1.97)     | 49.6 (1.24)     | 51.4 (1.98)     | <0.001  |
| Age                              | Age in years                                                          | 49 (1.9)        | 49.9 (2.04)     | 48.6 (1.68)     | <0.001  |
| Practice size                    | Number of patients older than 14 years old assigned to a PCP          | 17.193 (7576.8) | 11.977 (7331)  | 19.940 (6135)  | <0.001  |
| Residence                        | % of nursing home residents                                          | 0.73 (0.71)     | 1.03 (0.79)     | 0.57 (0.61)     | <0.001  |
| Immigration                      | % of immigration from a low-income country                           | 13 (7)          | 11.6 (5.83)     | 13.8 (7.45)     | 0.005   |
| Continuity of care               | % of change 2020–2019                                                 | –10.9 (10.1)    | –7.18 (9.17)    | –12.91 (10.0)   | <0.001  |
| VISUBA* GPs†                     | % of change 2020–2019 in GP                                           | –18.2 (24.9)    | –14.06 (22.0)   | –20.41 (26.0)   | 0.031   |
| VISUBA* nurses                   | % of change 2020–2019 in nurses                                      | –30.8 (29.8)    | –22.77 (22.0)   | –34.99 (32.5)   | <0.001  |
| COVID-19 cumulative incidence    | % of COVID-19                                                         | 15.1 (4.4)      | 13.4 (4.61)     | 16.0 (4.08)     | <0.001  |
| Face-to-face appointments         | weekly appointments offered per professional                         | 24.9 (15.1)     | 34.6 (15.8)     | 16.5 (9.37)     | <0.001  |
| Face-to-face appointments         | PCPs† with 0–10 weekly appointments per professional                 | 45 (15.7)       | 1 (1.01%)       | 44 (23.5%)      | <0.001  |
| Face-to-face appointments         | PCPs† with 11–25 weekly appointments per professional                | 140 (48.9)      | 29 (29.3%)      | 111 (59.4%)     |         |
| Face-to-face appointments         | PCPs† with 26–40 weekly appointments per professional                | 65 (22.7)       | 37 (37.4%)      | 28 (15.0%)      |         |
| Face-to-face appointments         | PCPs† with > 40 weekly appointments per professional                 | 36 (12.6)       | 32 (32.3%)      | 4 (2.14%)       |         |

*VISUBA: Percentage of appointments booked with an assigned professional; †GP: general practice; ‡PCP: primary care practices.
(95% CI: -22.3 to -20.2) and -33.7% (95% CI: -35.1 to -32.3), consistent with the reduction of HbA1c test and BP measures performed indicators: -18% (95% CI: -18.9 to -17.1) and -29.5% (95% CI: 30.8 to -28.1), respectively. In contrast, the percentage of T2DM patients with HbA1c > 10% increased by 34% (95% CI: 29.9 to 38.1).

A bivariate analysis using PCP characteristics showed that rural areas had significantly less reduction of T2DM indicators’ results and T2DM incidence (Table 3). The variable with the highest correlation with the reduction of the indicators was face-to-face appointment, highlighting the correlation of 0.55 (95% CI: 0.46 to 0.62, p-value < 0.05) with the HbA1c < 8% control indicator and the correlation of 0.51 (95% CI: 0.42 to 0.59, p-value < 0.05) with HbA1c test performed indicator. BP control and BP measure performed indicators were both correlated with the face-to-face variable by 0.43 (95% CI: 0.33 to 0.52, p-value < 0.05) and foot screening indicator by 0.39 (95% CI: 0.29 to 0.48, p-value < 0.05). Significant, though minor, statistical correlations were also found between face-to-face visits and T2DM incidence and an inverse correlation with HbA1c > 10% of -0.26 (95% CI: -0.37 to -0.15, p-value < 0.05) was observed. None of these correlations between face-to-face visits and results’ indicators were found in 2019 (supplementary Table S2). Other significant variables were practice size, percentage of women and continuity of care (Table 3). Covid-19 cumulative incidence had an inverse correlation with some indicators, except for the HbA1c > 10% indicator, the retinopathy screening indicator and T2DM incidence. No significant differences or correlations were observed between the retinopathy screening indicator and the explanatory variables.

Mean number of weekly face-to-face appointments per professional was reduced during the September-December period in 2020 compared with the same months in 2019: 49.7 (10.1) weekly face-to-face appointments on average in 2019 versus 24.9 (15.1) in 2020 (-50% reduction, p < 0.001). This reduction was higher in GP than in primary care nurses: 56.6 (12.0) weekly face-to-face appointments on average in 2019 vs 24.0 (15.0) in 2020 (-57.6% reduction, p < 0.001) and 42.8 (12.9) in 2019 and 26.5 (18.1) in 2020 (-38.2% reduction, p < 0.001), respectively. Supplementary Figure S1 depicts the average number of face-to-face appointments per professional by PCP (September - December 2020 period) to show the distribution of the variable; while Supplementary Figure S2 presents the number of face-to-face appointments and COVID-19 cases for context. Finally, Supplementary Figure S3 shows the mean number of face-to-face appointments in 2020 and 2019 to show this reduction and the increase of variability among the PCP.

Table 4 shows the percentage of change of each indicator by categories of the face-to-face variable. PCPs with less face-to-face appointments offered (from 0 to 10) had greater reductions of the indicators: -60.7% reduction of foot screening, -40.2% of BP control, -30.5% of T2DM incidence, -23.1% and -35.5% of HbA1c test and BP measure indicators respectively; and an increase of the indicator of HbA1c > 10% of 42.3%. Conversely, PCPs with >40 weekly face-to-face appointments per professional had statistically less reductions. In addition, in 9 out of 10 indicators we observed a gradient between face-to-face appointments and indicators’ reductions. However, no differences were observed between the number of weekly face-to-face appointments and the percentage of change of the retinopathy screening indicator.

### Table 2 – Percentage of change (with 95% CI) of T2DM indicators results and incidence between 2020 and 2019; and mean results in 2020 and 2019.

| Indicator                        | percentage of change (95% CI) | Mean (standard deviation) of 2019 results | Mean (standard deviation) of 2020 results |
|---------------------------------|------------------------------|------------------------------------------|------------------------------------------|
| Foot screening                  | -51.6 (53.9 to -49.4)        | 72.2 (4.9)                               | 35 (14.6)                               |
| Retinopathy screening           | -25.7 (26.9 to -24.5)        | 81.8 (4.2)                               | 60.8 (9.3)                               |
| HbA1c < 8%                      | -21.2 (22.3 to -20.2)        | 71 (3.7)                                 | 55.9 (7)                                 |
| HbA1c performed                 | -18.0 (18.9 to -17.1)        | 85.5 (3)                                 | 70.2 (7.5)                               |
| HbA1c < 8% performed            | -3.4 (3.7 to -3.1)           | 82.8 (3.1)                               | 79.9 (3.7)                               |
| HbA1c > 10%                     | 34.0 (29.9 to 38.1)          | 3.5 (1.2)                                | 4.5 (1.5)                                |
| BP < 150/95 mmHg                | -33.7 (35.1 to -32.3)        | 81.8 (3.2)                               | 54.2 (10.2)                              |
| BP performed                    | -29.5 (30.8 to -28.1)        | 87.6 (2.6)                               | 61.9 (10.6)                              |
| BP < 150/95 mmHg performed      | -7.6 (8.2 to -7.0)           | 83.3 (5.4)                               | 76.9 (6.3)                               |
| T2DM incidence*                 | -25.6 (27.9 to -23.3)        | 4.7 (1.3)                                | 3.4 (1)                                  |

*Incidence per 1,000 at risk population.
Table 3 – Percentage of change of T2DM indicators and incidence according to PCP characteristics: t-test or ANOVA for categorical variables and Pearson correlations for continuous variables.

| Categorical variables | Foot screening | Retinopathy screening | HbA1c performed | HbA1c < 8% performed | HbA1c > 10% performed | BP performed | BP < 150/95 mmHg performed | BP < 150/95 mmHg performed | T2DM incidence |
|-----------------------|----------------|-----------------------|------------------|----------------------|-----------------------|-------------|-----------------------------|-----------------------------|----------------|
| **Rurality**          |                |                       |                  |                      |                       |             |                             |                             |                |
| Rural                 | -4.1 (2.2)     | -24.3 (13.4)          | -12.5 (6.5)      | -14.4 (7.7)          | -1.8 (2.96)           | 20.1 (34.5) | -23.5 (11.7)                | -27.2 (12.9)                | -6.1 (4.8)     |
| Urban                 | -57.1 (15.4)   | -26.5 (8.4)           | -20.9 (7.1)      | -24.9 (7.7)          | -4.2 (2.3)            | 41.1 (33.8) | -32.6 (10.1)                | -37.1 (10.7)                | -8.4 (4.6)     |
| **p-value**           | <0.001         | 0.146                 | <0.001           | <0.001               | <0.001                | <0.001      |                             |                             | 0.03           |
| **Socioeconomic status** |               |                       |                  |                      |                       |             |                             |                             |                |
| % of Urban - Quartile 1 (Least deprived) | -61.0 (11.2) | -28.0 (5.4)           | -23.5 (6.5)      | -26.7 (7.1)          | -3.4 (1.4)            | 47.0 (40.3) | -37.3 (9.7)                 | -41.5 (10.1)                 | -7.8 (4.5)     |
| % of Urban - Quartile 2 | -56.2 (17.4) | -37.6 (10.2)          | -19.8 (7.1)      | -23.2 (7.7)          | -3.8 (2.3)            | 44.7 (36.6) | -31.7 (12.3)                | -35.2 (13.4)                | -7.5 (4.7)     |
| % of Urban - Quartile 3 | -56.0 (15.5) | -26.0 (9.4)           | -20.0 (7.3)      | -23.7 (7.8)          | -4.0 (2.2)            | 37.3 (29.5) | -30.8 (7.9)                 | -35.7 (8.4)                 | -8.9 (4.9)     |
| % of Urban - Quartile 4 (Most deprived) | -55.1 (16.9) | -24.7 (8.2)           | -20.2 (6.98)     | -25.6 (7.9)          | -5.5 (2.4)            | 37.8 (29.1) | -30.7 (9.6)                 | -35.9 (10.1)                | -8.9 (4.3)     |
| p-value               | <0.001         | 0.219                 | <0.001           | <0.001               | <0.001                | <0.001      |                             |                             | 0.081          |
| **Continuous variables** |               |                       |                  |                      |                       |             |                             |                             |                |
| Percentage of women   | -0.26* (0.37; -0.15) | 0 (0.12,0.11)       | -0.34* (0.43; -0.23) | -0.31* (0.41; -0.20) | -0.08 (0.19,0.04)       | 0.22* (0.10,0.33) | -0.33* (0.43; -0.23) | -0.31* (0.41; -0.20) | 0 (0.10,0.11) |
| Mean age              | 0.16* (0.05,0.27) | 0.08 (0.03,0.19)   | 0.17* (0.06,0.28)  | 0.26* (0.15,0.37)    | 0.39* (0.29,0.49)       | 0.15* (0.04,0.26) | 0.15* (0.01,0.26) | 0.15* (0.01,0.26) | 0.04 (0.15,0.08) |
| Practice size         | -0.29* (0.35; -0.14) | -0.09 (0.20,0.02)   | -0.41* (0.50; -0.33) | -0.44* (0.53; -0.34) | -0.37* (0.46; -0.26)   | 0.26 (0.15,0.36) | -0.3* (0.40; -0.19) | -0.27* (0.37; -0.16) | -0.04 (0.16,0.07) |
| % of nursing home patients | 0.18* (0.07,0.29) | 0.006 (0.10,0.12)   | 0.15* (0.04,0.27) | 0.17* (0.08,0.28) | 0.16* (0.04,0.27)       | -0.03 (0.14,0.09) | 0.16* (0.04,0.27) | 0.17* (0.06,0.28) | 0.09 (0.01,0.20) |
| Immigration           | 0 (0.10,0.12)    | -0.1* (0.20,0.01)   | 0.01 (0.11,0.12)  | -0.07 (0.18,0.05)    | -0.29* (0.35; -0.18)   | -0.02 (0.14,0.09) | 0.01 (0.10,0.13) | -0.01 (0.13,0.10) | -0.09 (0.21,0.02) |
| Continuity of care    | 0.31* (0.21,0.42) | 0.13 (0.02,0.25)   | 0.44* (0.35,0.54) | 0.45* (0.34,0.53) | 0.16* (0.06,0.29)       | -0.12* (0.24; -0.01) | 0.32* (0.21,0.42) | 0.34* (0.24,0.44) | 0.21* (0.13,0.33) |
| VISUBA†               | 0.21* (0.11,0.31) | 0.1 (0.01,0.22)     | 0.32* (0.12,0.42) | 0.39* (0.19,0.46) | 0.11 (0.00,0.23)       | -0.01 (0.13,0.03) | 0.20 (0.09,0.32) | 0.21* (0.11,0.33) | 0.13* (0.01,0.24) |
| Nurses                | 0.32* (0.21,0.42) | 0.18* (0.06,0.29)   | 0.36* (0.26,0.44) | 0.35* (0.25,0.45) | 0.16* (0.05,0.27)       | -0.06 (0.13,0.05) | 0.32* (0.22,0.43) | 0.33* (0.23,0.43) | 0.16* (0.04,0.27) |
| COVID-19 cumulative incidence | -0.2* (0.31; -0.09) | -0.11 (0.22,0.01)   | -0.18* (0.29; -0.07) | -0.27* (0.35; -0.14) | -0.31* (0.41; -0.20)   | 0.06 (0.06,0.17) | -0.18* (0.27; -0.05) | -0.17* (0.28; -0.06) | -0.18* (0.28; -0.06) |
| Face-to-face appointments | 0.39* (0.29,0.48) | 0.11 (0.00,0.27)   | 0.51* (0.42,0.58) | 0.55* (0.46,0.62) | 0.38* (0.27,0.47)       | -0.26* (0.37; -0.15) | 0.43* (0.33,0.52) | 0.42* (0.33,0.52) | 0.17* (0.06,0.28) |

*Correlations between indicators and variables are statistically significant. †VISUBA: Percentage of appointments booked with an assigned professional; †GP: general practice.
We hereby describe a reduction of foot and retinopathy reduction in our study. The reduction of face-to-face visits during the pandemic (50% HbA1c control and \( C_0 \)) practices with less than 11 weekly face-to-face appointments with the number of face-to-face consultations. Primary care previous year. In our study, these reductions were associated with T2DM during the covid-19 pandemic compared to the screening, HbA1c and BP control, and diagnosis of patients are provided in full in Supplementary Table S3.

Linear regression models were measured including the variables that showed a statistically significant correlation with the percentage of change of at least one of the indicators. After the adjustments, PCPs with > 40 weekly face-to-face appointments per professional and between 26 and 40 face-to-face appointments had lesser reductions on the foot screening indicator, the HbA1c control indicators and the BP control indicators. The explanatory powers of the models were moderate, ranging between 22% in the foot screening indicator and 39% in HbA1c < 8% indicator. The face-to-face variable also presented an effect on T2DM incidence reduction although the model after adjusting for other variables (more face-to-face appointments per professional and between 26 and 40 face-to-face visits and suggested that to benefit vulnerable patients with uncontrolled T2DM, in-person engagement may be required to be achieved by telephone only compared to face-to-face visits and to reduce patients and healthcare workers' direct exposure to infection.

Some studies suggest that telemedicine could compensate for part of this reduction of face-to-face visits [26–27]. However, we must distinguish between voluntary and patient-requested telemedicine with remarkable benefits, and a forced telemedicine as a consequence of the difficulty to contact in-person in the context of Covid-19 pandemic. Therefore, older patients or patients with difficulties in using technology may have been more affected by this forced change towards telehealth, as described elsewhere [28–29]. One study performed in uncontrolled diabetes mellitus patients in late 2020 showed that T2DM control was less likely to be achieved by telephone only compared to face-to-face visits and suggested that to benefit vulnerable patients with uncontrolled T2DM, in-person engagement may be required [30]. This is consistent with our results. Conversely, other studies didn’t find any difference in T2DM control between patients using telemedicine and not, but some were performed before the pandemic [31]. In a recent research letter, Patel et al. observed no evidence of a negative association between decrease in outpatient visits and medication fills or glycemic control [14] although they observed reductions of –6.5% in HbA1c testing and –18.8% in retinopathy testing in 2020 compared to 2019.

### Table 4 – Mean reductions (standard deviation) of T2DM indicators by face-to-face variable categories.

| Indicator                  | Mean number of face-to-face weekly appointments per professional |
|----------------------------|------------------------------------------------------------------|
|                            | 0–10 | 11–25 | 26–40 | >40  | p-value |
| Foot screening             | –60.7| –56.1 | –43.3 | –38.2| <0.001  |
| (15.7)                     | (15.8)| (21.3)| (22.2)|     |
| Retinopathy screening      | –27.1| –26.3 | –24.6 | –23.6| 0.324   |
| (8.4)                      | (8.8) | (12.9)| (13.0)|     |
| HbA1c performed            | –23.1| –19.9 | –14.2 | –11.0| <0.001  |
| (6.3)                      | (7.1) | (7.5) | (5.6) |     |
| HbA1c < 8%                 | –27.5| –23.5 | –16.8 | –12.5| <0.001  |
| (6.4)                      | (7.9) | (8.9) | (6.9) |     |
| HbA1c < 8% performed       | –4.6 | –3.9  | –2.7  | –1.2 | <0.001  |
| (1.9)                      | (2.5) | (2.8) | (3.3) |     |
| HbA1c > 10%                | 42.3 | 39.7  | 26.9  | 13.6 | <0.001  |
| (34.6)                     | (32.8)| (35.6)| (37.9)|     |
| BP performed               | –35.5| –31.9 | –24.9 | –20.9| <0.001  |
| (12)                       | (9.7) | (11.5)| (10.2)|     |
| BP < 150/95 mmHg           | –40.2| –36.3 | –28.9 | –24.3| <0.001  |
| (12.9)                     | (10.3)| (12.7)| (10.7)|     |
| BP < 150/95 mmHg performed| –8.2 | –8.0  | –7.4  | –5.4 | 0.02    |
| (5.2)                      | (4.4) | (4.9) | (5.0) |     |
| T2DM incidence             | –30.5| –27.8 | –21.0 | –18.3| 0.004   |
| (17.3)                     | (14.2)| (18.6)| (34.9)|     |

4. Discussion

We hereby describe a reduction of foot and retinopathy screening, HbA1c and BP control, and diagnosis of patients with T2DM during the covid-19 pandemic compared to the previous year. In our study, these reductions were associated with the number of face-to-face consultations. Primary care practices with less than 11 weekly face-to-face appointments offered per professional had greater reductions than those PCPs with more than 40. For instance, we found –60.7% reduction vs –38.2% in foot screening, –27.5% vs –12.5% in HbA1c control and –40.2 vs –24.3% in BP control, respectively.

These results are of interest due to the dramatic decrease of face-to-face primary care visits during the pandemic (50% reduction in our study). The reduction of face-to-face visits could be linked to several reasons, such as a change in health-seeking behaviour of the patients due to the fear of being infected by SARS-CoV-2 [25] and some organizational changes in primary care practices that reduced the number of face-to-face appointments and thus caused the access barriers to the outclinics. As our study analysed visits offered, we can indirectly assess the impact of some organizational changes produced during the pandemic, such as limiting the number of face-to-face appointments available in order to reduce patients and healthcare workers’ direct exposure to infection.

Linear regression models were measured including the variables that showed a statistically significant correlation with the percentage of change of at least one of the indicators. After the adjustments, PCPs with > 40 weekly face-to-face appointments per professional and between 26 and 40 face-to-face appointments had lesser reductions on the foot screening indicator, the HbA1c control indicators and the BP control indicators. The explanatory powers of the models were moderate, ranging between 22% in the foot screening indicator and 39% in HbA1c < 8% indicator. The face-to-face variable also presented an effect on T2DM incidence reduction after adjusting for other variables (more face-to-face appointments less incidence reduction) although the model only had a R2 of 7%. Face-to-face variables didn’t show any statistically significant effect in our models for the retinopathy screening indicator and the HbA1c > 10% indicator. Beta coefficients and R2 values of the models for each indicator are provided in full in Supplementary Table S3.

Some studies suggest that telemedicine could compensate for part of this reduction of face-to-face visits [26–27]. However, we must distinguish between voluntary and patient-requested telemedicine with remarkable benefits, and a forced telemedicine as a consequence of the difficulty to contact in-person in the context of Covid-19 pandemic. Therefore, older patients or patients with difficulties in using technology may have been more affected by this forced change towards telehealth, as described elsewhere [28–29]. One study performed in uncontrolled diabetes mellitus patients in late 2020 showed that T2DM control was less likely to be achieved by telephone only compared to face-to-face visits and suggested that to benefit vulnerable patients with uncontrolled T2DM, in-person engagement may be required [30]. This is consistent with our results. Conversely, other studies didn’t find any difference in T2DM control between patients using telemedicine and not, but some were performed before the pandemic [31]. In a recent research letter, Patel et al. observed no evidence of a negative association between decrease in outpatient visits and medication fills or glycemic control [14] although they observed reductions of –6.5% in HbA1c testing and –18.8% in retinopathy testing in 2020 compared to 2019.
Some results of our study deserve specific comments. Although we observed an association between indicators’ reductions and face-to-face appointment for 9 out of 10 indicators, we didn’t find any relation with retinopathy screening. This suggests that retinopathy screening is not associated with primary care face-to-face appointments. This can be explained because this screening usually requires a procedure performed outside primary care practices and during the first months of the pandemic this kind of procedure was partially halted in Catalonia. It is also possible that our study was not able to observe an association yet because retinopathy indicator requires a screening in a 2-year period and the reduction of face-to-face visits were mainly in the last 9 months.

The great reduction of HbA1c and BP control appear to be more related to a decline of HbA1c tests and BP measures performed. However, we also found an association between face-to-face appointments and control indicators when we excluded those patients that didn’t have a control performed. In addition, the percentage of T2DM patients with HbA1c > 10% had a greater increase in those practices with less face-to-face appointments. It is possible that PCPs with fewer face-to-face appointments offered would prioritize in-person visits from patients with known poor control and thus the result of this indicator increased, introducing a selection bias. However, it is also possible that the Covid-19 pandemic and the changes in social behaviours led to worsening control of T2DM as suggested in some studies, specially in those insulin-treated patients [9–10]. Finally, the reduction of registered T2DM incidence suggests an underdiagnosis during the Covid-19 pandemic previously described in chronic conditions in other articles [32].

Rural areas showed less reduction in results of T2DM-related indicators and T2DM incidence than urban PCPs. This could be related to several factors. Rural PCPs usually have smaller size than urban (both, less assigned population and less healthcare workers) and greater patients’ mean age, making it more difficult to change the organization towards other models. In fact, in our study only one rural PCP had less than 11 weekly face-to-face appointments offered per professional. Although the distribution of the face-to-face variable in rural and urban PCPs was significantly different, the effect of in-person visits remained after the adjustments, supporting the hypothesis discussed above. Furthermore, previous work has shown that rural areas had a lower percentage of COVID-19 [33]. In rural areas, then, health care professionals were aware about their epidemiological COVID situation with a lower impact compared to urban areas. That could explain its regular clinical practice (face-to-face) could have been less reduced compared to urban centers. Another important aspect is how citizens cope with this situation and also change their behaviour related to clinical contacts. In urban areas citizens may be more reluctant to accept face to face contacts and also they may miss some of the appointments already scheduled. These two aspects, clinical COVID situation and citizens risk perception could be another of the possible explanations of the described results. Further studies are needed in order to analyse in depth potential explanations from the outputs observed in rural and urban centers.

Our findings should be interpreted in the context of their limitations. First, we performed an ecological analysis and our methods do not allow us to ensure a causal correlation between the number of face-to-face appointments offered and the reduction of indicators’ results. Although other reasons may also play a role, the reductions of face-to-face visits analysed in our article have been one important issue during the pandemic, raising several concerns about future negative outcomes associated with poor control or delayed treatment [34]. Secondly, we did not analyse if telemedicine has compensated for some of the reductions observed on T2DM indicators. This could be the objective of future research. Thirdly, even though most of the indicators decreased, we cannot determine the direct impact on our patients’ health. Nonetheless, EQA has proven to be a good measure of our population’s health and its indicators have been used for more than a decade to measure health outcomes [19].

This study also has some strengths. EQA indicators have been shown to be useful in improving clinical situations [19]. The EQA indicator system and its criteria are also standardised across all centres and, therefore, our conclusions are scalable across Catalonia. Finally, our research has analysed different aspects of clinical practice of patients with T2DM which provide us with a global picture of the relation of face-to-face visits and the management of T2DM.

In conclusion, our study suggests that some organizational factors such as reducing the number of face-to-face visits offered to the population could have an impact on T2DM screening, diagnosis and glycemic and BP control. There is a need to recover face-to-face visits for all patients with chronic conditions to ensure a proper follow-up and control and to avoid future negative outcomes possibly associated.

Author contributions

EC designed the study, researched data, wrote the manuscript and acted as guarantor. QM researched data, performed statistical analysis and wrote the manuscript. MM designed the study, contributed to the discussion, reviewed the manuscript and acted as guarantor. XM designed the study and reviewed/edited the manuscript. XC reviewed/edited the manuscript and contributed to the discussion. MB performed the bibliographic search and reviewed the manuscript. AM designed the study, contributed to the discussion and reviewed the manuscript. MF contributed to the discussion and reviewed the manuscript. FF contributed to the discussion and reviewed the manuscript. YL contributed to the discussion and reviewed/edited the manuscript. JV designed the study, contributed to the discussion and reviewed/edited the manuscript.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper: [XC...
has acted as consultant, research support or speaker's bureau for AstraZeneca, Boehringer Ingelheim, Lilly, Novartis, Novo Nordisk and Sanofi Diabetes, Sanofi Pasteur and Esteve. The rest of the authors did not declare any competing interests].

Acknowledgments

The authors of this paper would like to thank all primary care professionals in Catalonia for their work and resilience providing care to the catalan population during these difficult times.

Appendix A. Supplementary material

Supplementary data to this article can be found online at https://doi.org/10.1016/j.diabres.2021.109127.

REFERENCES

[1] Santi L, Golinelli D, Tampieri A, Farina G, Greco M, Rosa S, Beleffi M, Biavati B, Campinoti F, Guerrini S, Ferrari R, Rucci P, Fantini MP, Giastra F. Non-COVID-19 patients in times of pandemic: Emergency department visits, hospitalizations and cause-specific mortality in Northern Italy. PLoS ONE 2021;16(5). https://doi.org/10.1371/journal.pone.0248555. PMID: 33750990; PMCID: PMC7984614.

[2] Levene LS, Seidu S, Greenhalgh T, Khunti K. Pandemic threatens primary care for long term conditions. BMJ 2020 Oct;5(371). https://doi.org/10.1136/bmj.m3793. PMID: 33020049 m3793.

[3] Pifarré i Arolas H, Vidal-Alaball J, Gil J, López F, Nicodemo C, Saez M. Missing Diagnoses during the COVID-19 Pandemic: A Year in Review. Int J Environ Res Public Health 2021;18(10):5335. https://doi.org/10.3390/ijerph18105335.

[4] Williams R, Jenkins DA, Ashcroft DM, Lilly, Novartis, Novo Nordisk and Sanofi Diabetes, Sanofi Pasteur and Esteve. The rest of the authors did not declare any competing interests].

[5] Pifarre’ i Arolas H, Bonet M, Mora N, Coma E, Ferran M, Me’ndez L, Iglesias B, Fina F, Medina M, et al. Primary care in the time of COVID-19: monitoring the effects of nationwide lockdown for containing coronavirus infection on worsening of glycosylated haemoglobin and increase in diabetes-related complications: A simulation model using multivariate regression analysis. Diabetes Metab Syndr. 2020;14(4):319–3. https://doi.org/10.1016/j.dsx.2020.03.014.

[6] Coma E, Ferran M, Me’ndez L, Iglesias B, Fina F, Medina M, et al. Characteristics of Citizens and Their Use of Teleconsultations in Primary Care in the Catalan Public Health System Before and During the COVID-19 Pandemic: Retrospective Descriptive Cross-sectional Study. J Med Internet Res. 2021 May 27;23(5):e28629. https://doi.org/10.2196/29629.

[7] Lopez Segui F, Fernandez Guillamet D, Pifarre’ i Arolas H, Marin Gomez X, Ruiz Comellas A, Ramirez Morros AM, Adroher Mas C, Vidal-Alaball J. Big data-based analysis to characterise and identify variations in the type of Primary Care visits before and during COVID in Catalonia. J Med Internet Res. 12/06/2021:29622 (forthcoming/in press)

[8] Joy M, McCaggh D, Jones N, Liyanage H, Sherlock J, Parimalanathan V, et al. Reorganisation of primary care for older adults during COVID-19: a cross-sectional database study in the UK. Br J Gen Pract 2020;70(697):e540–7. https://doi.org/10.3399/bjgp20X710933.

[9] Biamonte E, Pogoraro F, Carrone F, Facchi I, Favacchio G, Lania AG, et al. Weight change and glycemic control in type 2 diabetes patients during COVID-19 pandemic: the lockdown effect. Endocrine 2021;72(3):604–10. https://doi.org/10.1007/s12020-021-02739-5.

[10] Karatas S, Yesim T, Betsy S. Impact of lockdown COVID-19 on metabolic control in type 2 diabetes mellitus and healthy people. Prim Care Diabetes. 2021;15(3):424–7. https://doi.org/10.1016/j.pcd.2021.01.002.

[11] Fisher L, Polonsky W, Asuni A, Jolly Y, Hessler D. The early impact of the COVID-19 pandemic on adults with type 1 or type 2 diabetes: A national cohort study. J Diabetes Complications 2020;34(12):107748. https://doi.org/10.1016/j.jdiaco.2020.107748.

[12] Ghosal S, Sinha B, Majumder M, Misra A. Estimation of effects of nationwide lockdown for containing coronavirus infection on worsening of glycosylated haemoglobin and increase in diabetes-related complications: A simulation model using multivariate regression analysis. Diabetes Metab Syndr. 2020;14(4):319–3. https://doi.org/10.1016/j.dsx.2020.03.014.

[13] Khader Mohammed Abdul, Jabeen Talha, Namoum Ramanachary. A cross-sectional study reveals severe disruption in glycemic control in people with diabetes during and after lockdown in India. Diabetes Metab Syndr Nov-Dec. 2020;14(6):1579–84.

[14] Patel SY, McCoy RG, Barnett ML, Shah ND, Mehrotra A. Diabetes Care and Glycemic Control During the COVID-19 Pandemic in the United States. JAMA Intern Med. Published online July 06, 2021. doi:10.1001/jama.2021.3047

[15] Schers H, van Weel C, van Boven K, Akkermans R, Bischoff E, Olde Hartman T. The COVID-19 Pandemic in Nijmegen, the Netherlands: Changes in Presented Health Problems and Demand for Primary Care. Ann Fam Med. 2021;19(1):44–7. https://doi.org/10.1370/afm.2625.

[16] McColl A, Roderick P, Gabbay J, Smith H, Moore M. Performance indicators for primary care groups: an evidence based approach. BMJ 1998;317(7169):1554–60. https://doi.org/10.1136/bmj.317.7169.1554.

[17] Bodicoat DH, Mendum T, Davies MJ, Khunti K, Roura F, Franch J, Mata-Cases M, Cos X, Francisco Cano J. GEDAPS Study Group. The impact of a programme to improve quality of care for people with type 2 diabetes on hard to reach groups: The GEDAPS study. Prim Care Diabetes 2015;9(3):211–18. https://doi.org/10.1016/j.pcd.2014.08.001. Epub 2014 Sep 1. PMID: 25189137.

[18] Comín E, Catalan-Ramos A, Iglesias-Rodal M, Grau M, Del Val JL, Consola A, Amado E, Pons A, Mata-Cases M, Franzí A, Ciurana R, Frigolá E, Cos X, Davins J, Verdu-Rottell JM. Impact of implementing electronic clinical practice guidelines for the diagnosis, control and treatment of cardiovascular risk factors: A pre-post controlled study. Aten Primaria 2017;49(7):389–98. https://doi.org/10.1016/j.apt.2016.11.007. Epub 2017 Mar 15. PMID: 28314542; PMCID: PMC6875959.

[19] Coma E, Ferran M, Méndez L, Iglesias B, Fina F, Medina M. Creation of a synthetic indicator of quality of care as a clinical management standard in primary care. Springerplus 2013;2(1):51. https://doi.org/10.1186/2193-1801-2-51.

[20] Coma Redón E, Méndez BL. SISAP: 4 años buceando en mares de datos. AMF. 2010;6(8):473–7.

[21] García-Gil M, Elorza JM, Banque M, et al. Linking of primary care records to census data to study the association between socioeconomic status and cancer incidence in Southern Europe: a nation-wide ecological study. PLoS One. 2014;9(10):e109706.
[22] Saultz JW. Defining and measuring interpersonal continuity of care. Ann Fam Med. 2003;1(3):134–43. https://doi.org/10.1370/afm.23.

[23] Coma E, Mora N, Peremiquel-Trillas F, Benítez M, Méndez L, Mercadé A, et al. Influence of organization and demographic characteristics of primary care practices on continuity of care: analysis of a retrospective cohort from 287 primary care practices covering about 6 million people in Catalonia. BMC Fam Pract 2021;22(1). https://doi.org/10.1186/s12875-021-01414-y.

[24] R Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2018. https://www.R-project.org/. Accessed 10 July 2021.

[25] Harper CA, Satchell LP, Fido D, et al. Functional fear predicts public health compliance in the COVID-19 pandemic. Int J Ment Health Addict 2020;27:1–14. https://doi.org/10.1007/s11469-020-00281-5.

[26] Vidal-Alaball Josep, Acosta-Roja Ruthy, Hernández Nuria Pastor, Luque Unai Sanchez, Morrison Danielle, Pérez Silvia Narejos, Perez-Llano Jesús, Vérgez Angels Salvador, Seguí Francesc López. Telemedicine in the face of the COVID-19 pandemic. Atención Primaria 2020;52(6):418–22. https://doi.org/10.1016/j.aprim.2020.04.003. ISSN 0212-6567.

[27] Alromaihi D, Alamuddin N, George S. Sustainable diabetes care services during COVID-19 pandemic. Diabetes Res Clin Pract. 2020;166. https://doi.org/10.1016/j.diabres.2020.108298. Epub 2020 Jul 3. PMID: 32620301; PMCID: PMC7332426.

[28] S Gomes-de Almeida, T Marabujo, M do Carmo-Gonçalves. Telemedicine satisfaction of primary care patients during COVID-19 pandemics Semergen May-Jun 2021;47(4):248-255. 10.1016/j.semerger.2021.01.005. Epub 2021 Mar 11

[29] Florea Mira, Lazea Cecilia, Gaga Remus, Sur Genel, Lotrean Lucia, Puia Aida, et al. Lights and Shadows of the Perception of the Use of Telemedicine by Romanian Family Doctors During the COVID-19 Pandemic. Int J Gen Med 2021;14:1575-87.

[30] Turner BJ, Liang Y, Ramachandran A, Poursani R. Telephone or Visit-Based Community Health Worker Care Management for Uncontrolled Diabetes Mellitus: A Longitudinal Study. J Community Health 2020;45(6):1123–31. https://doi.org/10.1007/s10900-020-00849-1.

[31] Verhoeven P, Tanja-Dijkstra K, Nijland N, Eysenbach G, van Gemert-Pijnen L. Asynchronous and synchronous teleconsultation for diabetes care: a systematic literature review. J Diabetes Sci Technol 2010;4(3):666–84. https://doi.org/10.1177/193229681000400323. Published 2010 May 1.

[32] Siso-Almirall, Antoni; Kostov, Belchin; Sánchez, Encarna; Benavent-Áreu, Jaume; González-de-Paz, Luis. The impact of the Covid-19 pandemic on primary healthcare disease incidence rates: 2017 TO 2020. Preprint AFM-126-21 https://deepblue.lib.umich.edu/bitstream/handle/2027.42/167403/AFM-126-21_PP.pdf?sequence=1&isAllowed=y Accessed on July 20 2021

[33] Marin-Gomez FX, Fabregas-Escurriola M, Segui FL, Perez EH, Camps MB, Peña JM, Cormellas AR, Vidal-Alaball J. Assessing the likelihood of contracting COVID-19 disease based on a predictive tree model: A retrospective cohort study. PLoS One 2021;16(3). https://doi.org/10.1371/journal.pone.0247995. PMID: 33657164; PMCID: PMC7928490.

[34] Paul SK, Klein K, Thorsted BL, Wolden ML, Khunti K. Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes. Cardiovasc Diabetol. 2015 Aug;7(14):100. https://doi.org/10.1186/s12933-015-0260-x. PMID: 26249018; PMCID: PMC4528846.